CN109172550B - Composite anesthetic - Google Patents
Composite anesthetic Download PDFInfo
- Publication number
- CN109172550B CN109172550B CN201811437728.5A CN201811437728A CN109172550B CN 109172550 B CN109172550 B CN 109172550B CN 201811437728 A CN201811437728 A CN 201811437728A CN 109172550 B CN109172550 B CN 109172550B
- Authority
- CN
- China
- Prior art keywords
- anesthetic
- anesthesia
- vitamin
- amino
- propofol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000003444 anaesthetic effect Effects 0.000 title claims abstract description 100
- 239000002131 composite material Substances 0.000 title description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 64
- OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229960004134 propofol Drugs 0.000 claims abstract description 33
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 32
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 32
- 239000011718 vitamin C Substances 0.000 claims abstract description 32
- 150000001875 compounds Chemical class 0.000 claims abstract description 22
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 12
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 12
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 7
- 239000004472 Lysine Substances 0.000 claims description 7
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 7
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 claims description 7
- 229960003908 pseudoephedrine Drugs 0.000 claims description 7
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 45
- 229940079593 drug Drugs 0.000 abstract description 26
- 229940024606 amino acid Drugs 0.000 abstract description 24
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 23
- 229960001690 etomidate Drugs 0.000 abstract description 18
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 abstract description 18
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 15
- 229960003299 ketamine Drugs 0.000 abstract description 15
- 239000003193 general anesthetic agent Substances 0.000 abstract description 8
- -1 acetylsalicylic acid, amino acids Chemical class 0.000 abstract description 7
- 210000004556 brain Anatomy 0.000 abstract description 3
- 210000002216 heart Anatomy 0.000 abstract description 2
- 210000003734 kidney Anatomy 0.000 abstract description 2
- 210000000056 organ Anatomy 0.000 abstract description 2
- 206010002091 Anaesthesia Diseases 0.000 description 40
- 230000037005 anaesthesia Effects 0.000 description 40
- 150000001413 amino acids Chemical class 0.000 description 17
- 230000006698 induction Effects 0.000 description 17
- 239000007924 injection Substances 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 238000012423 maintenance Methods 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 10
- 230000008034 disappearance Effects 0.000 description 10
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 9
- 238000010171 animal model Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000000147 hypnotic effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 4
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- PECIYKGSSMCNHN-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 4
- 229960003556 aminophylline Drugs 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 238000002695 general anesthesia Methods 0.000 description 4
- 229960002003 hydrochlorothiazide Drugs 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000011514 reflex Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 210000000683 abdominal cavity Anatomy 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000005286 illumination Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000004081 narcotic agent Substances 0.000 description 3
- 230000002746 orthostatic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000000004 hemodynamic effect Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000002690 local anesthesia Methods 0.000 description 2
- 229960003646 lysine Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022773 Intracranial pressure increased Diseases 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000005261 decarburization Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 229940005494 general anesthetics Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 201000009941 intracranial hypertension Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a compound anesthetic, which comprises the following active components: amino drugs, acetylsalicylic acid, amino acids, vitamin C, clinical anesthetic drugs; the clinical anesthetic is propofol, etomidate and ketamine. The invention reduces the content of the anesthetic by combining the clinical anesthetic with the amino medicine, acetylsalicylic acid, amino acid and vitamin C, thereby achieving the purpose of reducing side effects, especially reducing the damage to important organs such as brain, heart, kidney and the like.
Description
Technical Field
The invention belongs to an anesthetic in the field of medicines, and particularly relates to a compound anesthetic.
Background
Narcotics are drugs that cause temporary, reversible loss of consciousness and pain sensation throughout the body or parts of the body. The root anesthetic is divided into two kinds, general anesthetic and local anesthetic. General anesthetics inhibit cerebral cortex from shallow to deep, so that the mind of people disappears. Local anesthesia can stabilize the membrane potential of the nerve or reduce the permeability of the membrane to sodium ions, block the conduction of nerve impulse, and play a role in local anesthesia. At present, although clinical anesthetics are quite diverse and long, each anesthetic does not fully meet the idealized standards of clinical anesthesia.
Narcotics are necessary drugs for clinical surgery, including propofol, etomidate, ketamine, sodium thiopentetate, and the like. Although these drugs have side effects, they all meet the clinical medication safety requirements at present. For example, propofol has been widely used for anesthesia induction and maintenance in various types of surgery after more than ten years of development, and has become a first-line drug for Intensive Care (ICU) sedation due to its rapid onset of action and short maintenance time. However, the drug also has side effects, respiratory and circulatory inhibition is most obvious during anesthesia induction, and due to the dual effects of peripheral vasodilation and direct cardiac inhibition, especially when an induction dose is used, the inhibition effect on the cardiovascular circulatory system is obvious, mainly hypotension is shown, even though no related cardiovascular disease history exists, the contraction depression can be reduced by 25-40% by the induction of the low dose of propofol, and the inhibition effect is more obvious along with the increase of the dose and the drug concentration in blood, and the patients with the apneas are often seen. These disadvantages greatly restrict the clinical application and development of propofol, for example, in the elderly population, the brain becomes more sensitive to propofol with age, and the clearance rate of propofol is significantly reduced, which may lead to problems such as insufficient anesthesia depth, delayed recovery, etc. due to hemodynamic changes. For example, etomidate has a plurality of unique advantages and is applied to clinical anesthesia, and is suitable for patients such as elderly people who are complicated with cardiovascular diseases, respiratory systems, intracranial hypertension and other diseases and are not suitable for other medicines, but the medicine also has side effects such as convulsion, severe nausea and vomiting after operation, inhibited adrenal cortex function and the like.
Although the use of some drugs prior to surgery can reduce the amount of narcotics such as imidazole tranquilizer, narcotic analgesics, beta blockers, calcium channel blockers, melatonin, etc., problems such as effects on psychomotor function, sleep patterns, hemodynamics, and high price are faced. Therefore, how to reduce the dosage of the anesthetic, reduce the side effect of the anesthetic, reduce the adverse reaction of the anesthetic, achieve better anesthetic effect, and realize balanced anesthesia and reasonable anesthesia is one of the difficulties in the anesthesia field.
Disclosure of Invention
In order to solve the defects of large dosage and large side effect of the existing anesthetic, the invention provides a compound anesthetic, which comprises the following active components: amino drugs, acetylsalicylic acid, amino acids, vitamin C, clinical anesthetic drugs; the clinical anesthetic is propofol, etomidate and ketamine.
As a preferred embodiment of the present invention, the amount of the clinical anesthetic is not less than 50% of the maximum effective amount of vitamin C.
As a preferable technical scheme of the invention, the amino acid is selected from one or more of arginine, lysine and histidine.
As a preferable technical scheme of the invention, the PH of the composite anesthetic is more than 6.5.
As a preferable technical scheme, the amino medicament pseudoephedrine, aminophylline tablets, epinephrine and hydrochlorothiazide.
As a preferable technical scheme of the invention, the mass content of the amino medicine is 0.1-1% of that of the compound anesthetic.
As a preferable technical scheme of the invention, the clinical anesthetic is propofol, and the weight parts of the active components are as follows: 0.1-1 part of amino medicament, 2-5 parts of acetylsalicylic acid, 2-10 parts of amino acid, 10-15 parts of vitamin C and 30-40 parts of propofol.
As a preferable technical scheme of the invention, the clinical anesthetic is etomidate, and the contents of the components are as follows: 0.1-1 part of amino medicament, 1-5 parts of acetylsalicylic acid, 1-5 parts of amino acid, 10-15 parts of vitamin C and 4-10 parts of etomidate.
As a preferable technical scheme of the invention, the clinical anesthetic is ketamine, and the contents of the components are as follows: 0.1-1 part of amino medicine, 1-5 parts of acetylsalicylic acid, 10-15 parts of vitamin C and 35-47 parts of ketamine.
The invention provides a compound anesthetic. The anesthetic is an anesthetic injection prepared from amino drugs, acetylsalicylic acid, amino acid, vitamin C and clinical anesthetic. The acetylsalicylic acid, the amino medicine, the amino acid and the vitamin C are added into the anesthetic drugs of propofol, etomidate and ketamine, so that the content of the anesthetic is reduced when the same anesthetic effect is achieved, the purposes of reducing side effects of the anesthetic, particularly damage to important organs such as brain, heart, kidney and the like are achieved, the problems of large dosage and large side effects of the traditional clinical anesthetic are solved, and discomfort of a patient in the treatment process can be remarkably reduced. The invention overcomes the side effect of reducing the blood pressure of patients in the use process of the traditional anesthetic by using a small amount of amino medicaments and the anesthetic in a matched way and enabling the compound anesthetic to participate in the acetylsalicylic acid. In particular, the propofol is particularly obvious as the active ingredient of the anesthetic. Meanwhile, the vitamin C and the amino acid are matched for use, so that the content of the anesthetic is greatly reduced under the condition of achieving the same anesthetic effect, and particularly, the propofol is particularly obvious as the effective component of the anesthetic. The possible reasons are that the intravenous anesthetic commonly used clinically at present has antioxidant and free radical scavenging activities, so that the anesthetic entering the organism has anesthetic and antioxidant effects; the inventor adds vitamin C to play an antioxidant auxiliary role, so that the anesthetic can fully exert the anesthetic effect, and meanwhile, the added amino acid is basic amino acid, and the basic part of the amino acid can act with the acidic part of the propofol so as to inhibit the propofol from being oxidized, thereby reducing the dosage of the anesthetic under the condition of reaching the same anesthetic maintenance time. Particularly, when the patient has the effect that the propofol is an anesthetic, the injection pain of the compound anesthetic provided by the invention is obviously weakened, and the side effect of the anesthetic is obviously reduced.
Detailed Description
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. In case of conflict, the present specification, definitions, will control.
A compound anesthetic comprises the following active components: amino drugs, acetylsalicylic acid, amino acids, vitamin C, clinical anesthetic drugs; the clinical anesthetic is propofol, etomidate and ketamine.
As a preferred embodiment of the present invention, the amount of the clinical anesthetic is not less than 50% of the maximum effective amount of vitamin C.
As a preferred embodiment of the present invention, the amino acid is selected from one or more of arginine, lysine and histidine.
As a preferred embodiment of the present invention, the pH of the complex anesthetic is greater than 6.5.
As a preferred embodiment of the invention, the amino drugs pseudoephedrine, aminophylline tablets, epinephrine and hydrochlorothiazide.
As a preferred embodiment of the invention, the mass content of the amino medicine is 0.1-1% of that of the compound anesthetic.
As a preferred embodiment of the invention, the clinical anesthetic is propofol, and the weight parts of the active components are as follows: 0.1-1 part of amino medicament, 2-5 parts of acetylsalicylic acid, 2-10 parts of amino acid, 10-15 parts of vitamin C and 30-40 parts of propofol.
As a preferred embodiment of the invention, the clinical anesthetic is etomidate, and the contents of the components are as follows: 0.1-1 part of amino medicament, 1-5 parts of acetylsalicylic acid, 1-5 parts of amino acid, 10-15 parts of vitamin C and 4-10 parts of etomidate.
As a preferred embodiment of the invention, the clinical anesthetic is ketamine, and the contents of the components are as follows: 0.1-1 part of amino medicine, 1-5 parts of acetylsalicylic acid, 10-15 parts of vitamin C and 35-47 parts of ketamine.
The invention relates to a method for preparing a mixed and packaged compound anesthetic injection, which comprises the following steps:
1) Adding the existing clinical anesthetic into a preparation container according to the corresponding dosage of the concentration of the active component in the injection, dissolving with water for injection, adding the corresponding amount of the active component amino medicine, acetylsalicylic acid, amino acid and vitamin C, uniformly stirring, adjusting the pH value to 6.5-8.5, and adding fat emulsion or water for injection to the full amount;
2) Adding 0.3% of active carbon (subjected to dry heat treatment) in weight-volume ratio, stirring and adsorbing for 10-20 min, and sequentially performing rough filtration and decarburization by a titanium rod filter, filtration by a 0.45 mu m cylinder filter and fine filtration by a 0.22 mu m cylinder filter until the clarity is qualified;
3) After the content is determined to be qualified, the components are arranged in penicillin bottles (according to the applicable filling amount specification, for example, 20 mL/bottle), tamponade, cap pricking and sealing are carried out, and the compound anesthetic injection is obtained.
The embodiments and specific operation procedures are given on the premise of the technical scheme of the invention, but the protection scope of the invention is not limited to the following embodiments.
The composition content in the test mark in the invention is the content of each effective component of 10g of the composite anesthetic of the invention prepared by each group.
The methods used in the following examples and experiments are conventional methods unless otherwise specified.
Example 1 Combined use of Propofol as an anesthetic
1. Experimental animal
Clean grade C57BL/6J, male, 6-7 weeks old, body weight 20+ -2 g, purchased from Beijing Vietnam laboratory animal company; the room temperature is 23+/-2 ℃ and the fluorescent lamp illumination is 7:00-19:00. Mice were acclimatized to the laboratory environment for at least 1 week, fed free with water, and subjected to the experiment for a fixed time daily (10:00-12:00) and kept the laboratory environment quiet before the experimental formally started.
2. Use of drugs
Propofol, vitamin C, lysine, pseudoephedrine, acetylsalicylic acid.
3. Method of
The injection of the drugs establishes a general anesthesia induction model of the propofol of the mice, all the drugs are injected into the abdominal cavity, and each mouse is randomly divided into 1-18 groups according to the dosage of 2.7mg/kg by weight injection.
4. Observing and recording indexes
Dose thresholds for each group (3-5 replicates per dose) were determined using an asymptotic method, and the normative choice of hypnosis (i.e., the state of anesthesia) was simple and feasible to perform, and the anesthesia induction time to the disappearance of the normative reflex and the duration of the disappearance of the normative reflex (anesthesia maintenance time) were observed and recorded.
5. Experimental results
Recording: aiming at an experimental group capable of entering an anesthetic state, the anesthesia induction time from the time of administering to the time when the orthotopic reflection of the mice disappears is between 5 and 7min, and the anesthesia maintenance time is between 5 and 14min, so that the anesthesia experimental standard is met (the anesthesia induction time is less than or equal to 10min, and the anesthesia maintenance time is more than or equal to 5 min).
The experimental results are shown in Table 1-1:
table 1-1 results of the combination of the anesthetic propofol with vitamin C, lysine, pseudoephedrine, acetylsalicylic acid.
Note that: '++' indicates an anesthetic phenomenon in which the occurrence of the specular reflection disappears; ' indicates that no anesthesia phenomenon of disappearance of the specular reflection occurs.
Example 2 Combined use of etomidate as an anesthetic
1. Experimental animal
Clean grade C57BL/6J, male, 6-7 weeks old, body weight 20+ -2 g, purchased from Beijing Vietnam laboratory animal company; the room temperature is 23+/-2 ℃ and the fluorescent lamp illumination is 7:00-19:00. Mice were acclimatized to the laboratory environment for at least 1 week, fed free with water, and subjected to the experiment for a fixed time daily (10:00-12:00) and kept the laboratory environment quiet before the experimental formally started.
2. Use of drugs
Etomidate, vitamin C, arginine, aminophylline tablets, acetylsalicylic acid.
2. Method of
The injection of the medicine establishes a general anesthesia induction model of the mouse etomidate, all the medicines are injected into the abdominal cavity, and each mouse is randomly divided into 1-18 groups according to the dosage of 2.7mg/kg by weight injection.
3. Method of
The injection of the drug establishes a general anesthesia induction model of the mouse etomidate, and all the drugs are administrated by intraperitoneal injection.
4. Observing and recording indexes
The dose threshold for purely administering the mice to a hypnotic state (3-5 doses each) was determined by the asymptotic method, and the normative choice for hypnotic (i.e., anesthetic state) was simple and easy to apply to the eversion, and the anesthesia induction time until the eversion disappeared and the duration of the eversion (anesthesia maintenance time) were observed and recorded.
5. Experimental results
Recording: aiming at an experimental group capable of entering an anesthetic state, the anesthesia induction time from the time of administering to the time when the orthotopic reflection of the mice disappears is between 5 and 7min, and the anesthesia maintenance time is between 5 and 14min, so that the anesthesia experimental standard is met (the anesthesia induction time is less than or equal to 10min, and the anesthesia maintenance time is more than or equal to 5 min).
The experimental results are shown in Table 2-1:
TABLE 2-1 results of combination of etomidate with vitamin C, arginine, aminophylline tablet, acetylsalicylic acid
Note that: '++' indicates an anesthetic phenomenon in which the occurrence of the specular reflection disappears; ' indicates that no anesthesia phenomenon of disappearance of the specular reflection occurs.
Example 3 Combined use of ketamine as an anesthetic
1. Experimental animal
Clean grade C57BL/6J, male, 6-7 weeks old, body weight 20+ -2 g, purchased from Beijing Vietnam laboratory animal company; the room temperature is 23+/-2 ℃ and the fluorescent lamp illumination is 7:00-19:00. Mice were acclimatized to the laboratory environment for at least 1 week, fed free with water, and subjected to the experiment for a fixed time daily (10:00-12:00) and kept the laboratory environment quiet before the experimental formally started.
2. Use of drugs
Acetylsalicylic acid, vitamin C, hydrochlorothiazide and ketamine.
3. Method of
The injection of the drugs establishes a general anesthesia induction model of the ketamine of the mice, all the drugs are injected into the abdominal cavity, and each mouse is randomly divided into 1-15 groups according to the dosage of 2.7mg/kg by weight injection.
4. Observing and recording indexes
The dose threshold for purely administering the mice to a hypnotic state (3-5 doses each) was determined by the asymptotic method, and the normative choice for hypnotic (i.e., anesthetic state) was simple and easy to apply to the eversion, and the anesthesia induction time until the eversion disappeared and the duration of the eversion (anesthesia maintenance time) were observed and recorded.
5. Experimental results
Recording: aiming at an experimental group capable of entering an anesthetic state, the anesthesia induction time from the time of administering to the time when the orthotopic reflection of the mice disappears is between 5 and 7min, and the anesthesia maintenance time is between 5 and 14min, so that the anesthesia experimental standard is met (the anesthesia induction time is less than or equal to 10min, and the anesthesia maintenance time is more than or equal to 5 min).
The experimental results are shown in Table 3-1:
TABLE 3 results of combination of ketamine with acetylsalicylic acid, vitamin C, hydrochlorothiazide
Note that: '++' indicates an anesthetic phenomenon in which the occurrence of the specular reflection disappears; ' indicates that no anesthesia phenomenon of disappearance of the specular reflection occurs.
Discussion of experimental results:
from the experiments in Table 1-1, it can be seen in the groups 1 and 2 that no anesthesia phenomenon of disappearance of the specular reflection occurs when propofol is used as an anesthetic in an amount of less than 80mg/10 g. Comparison of groups 10 and 11 shows that no anesthesia occurs with the disappearance of the specular reflection when vitamin C is added and no amino acid is added when the amount of propofol is less than 60mg/10 g. Comparison of groups 2 and 4 shows that when propofol is used in an amount of 60mg/10g, the addition of vitamin C can produce an anaesthetic which is absent from the orthostatic reflex. Compared with the 1,2 and 3 groups, the compound anesthetic can keep normal blood pressure while the anesthetic effect is achieved when the amino medicine and the acetylsalicylic acid are added.
From the experimental table 2-1, it can be seen in the comparison of groups 1 and 2 that the anesthetic phenomenon of disappearance of the eversion front does not occur when etomidate is used as the anesthetic in an amount of less than 6 mg/g. Comparison of groups 10 and 11 shows that when etomidate is used in an amount of less than 5mg/10g, no loss of orthostatic anesthesia occurs when vitamin C is added and no amino acid is added. Comparison of groups 2 and 4 shows that when etomidate is used at a level of 5mg/10g, the addition of vitamin C can cause anesthesia with loss of orthostatic reflex. Compared with the 1,2 and 3 groups, the compound anesthetic can keep normal blood pressure while the anesthetic effect is achieved when the amino medicine and the acetylsalicylic acid are added.
From the experimental table 3-1, it can be seen from the comparison of groups 1 and 2 that the anesthesia phenomenon of the disappearance of the eversion and the specular reflection does not occur when ketamine is used as the anesthetic in an amount of less than 84mg/10 g. Comparison of groups 2 and 4 shows that when ketamine is used in an amount of 65mg/10g, the addition of vitamin C can cause anesthesia with the disappearance of the specular reflection. Compared with the 1,2 and 3 groups, the compound anesthetic can keep normal blood pressure while the anesthetic effect is achieved when the amino medicine and the acetylsalicylic acid are added.
The invention provides a compound anesthetic. The anesthetic is an anesthetic injection prepared from amino drugs, acetylsalicylic acid, amino acid, vitamin C and clinical anesthetic. The invention overcomes the side effect of reducing the blood pressure of patients in the use process of the traditional anesthetic by using a small amount of amino medicaments and the anesthetic in a matched way and enabling the compound anesthetic to participate in the acetylsalicylic acid. In particular, the propofol is particularly obvious as the active ingredient of the anesthetic. Meanwhile, the vitamin C and the amino acid are matched for use, so that the content of the anesthetic is greatly reduced under the condition of achieving the same anesthetic effect, and particularly, the propofol is particularly obvious as the effective component of the anesthetic. The added amino acid is basic amino acid, and the basic part of the amino acid can act with the acidic part of the propofol so as to inhibit the propofol from being oxidized, thereby reducing the dosage of anesthetic drugs under the condition of reaching the same anesthesia maintenance time.
Claims (3)
1. A compound anesthetic, characterized in that the compound anesthetic comprises the following components: 60mg/10g of propofol, 30 mg/10g of vitamin C, 3mg/10g of pseudoephedrine, 1mg/10g of acetylsalicylic acid and 2mg/10g of lysine.
2. A compound anesthetic, characterized in that the compound anesthetic comprises the following components: propofol 50mg/10g, vitamin C50 mg/10g, pseudoephedrine 3mg/10g, acetylsalicylic acid 1mg/10g, lysine 6mg/10g.
3. A compound anesthetic, characterized in that the compound anesthetic comprises the following components: 40mg/10g of propofol, 60mg/10g of vitamin C, 2mg/10g of pseudoephedrine, 1mg/10g of acetylsalicylic acid and 12mg/10g of lysine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811437728.5A CN109172550B (en) | 2018-11-29 | 2018-11-29 | Composite anesthetic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811437728.5A CN109172550B (en) | 2018-11-29 | 2018-11-29 | Composite anesthetic |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109172550A CN109172550A (en) | 2019-01-11 |
| CN109172550B true CN109172550B (en) | 2023-12-19 |
Family
ID=64938367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811437728.5A Active CN109172550B (en) | 2018-11-29 | 2018-11-29 | Composite anesthetic |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109172550B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110179888A (en) * | 2019-06-19 | 2019-08-30 | 武汉圣润生物科技有限公司 | A kind of arcotic oral solution and preparation method thereof for gastric operation |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103263404A (en) * | 2012-04-28 | 2013-08-28 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Composite anaesthetic |
-
2018
- 2018-11-29 CN CN201811437728.5A patent/CN109172550B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103263404A (en) * | 2012-04-28 | 2013-08-28 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Composite anaesthetic |
Non-Patent Citations (6)
| Title |
|---|
| Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects;Ruin Moaddel等;《Psychopharmacology (Berl)》;20181018;第235卷(第10期);3017–3030 * |
| 丙泊酚中加入麻黄碱诱导时病人血压的变化;沈立军等;《临床麻醉学杂志》;20010831;第17卷(第8期);458-459 * |
| 丙泊酚诱导时加入麻黄碱可有效防止血压下降及心率减慢;陈琼辉;《医学创新研究》;20071130;第4卷(第33期);49 * |
| 哌甲酯、氯安酮长期作用对大鼠海马游离氨基酸和皮层下组织多巴胺的影响;许崇涛等;《汕头大学医学院学报》;19961231(第1 期);4-8 * |
| 王求淦主编.伪麻黄碱.《新编实用临床药物手册》.广东科技出版社,2010,247. * |
| 韩启德总主编.为什么阿司匹林能镇痛.《十万个为什么（第六版）》.上海少年儿童出版社,2013,52-53. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109172550A (en) | 2019-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gurbet et al. | Intraoperative infusion of dexmedetomidine reduces perioperative analgesic requirements | |
| GOODING et al. | Etomidate: an ultrashort-acting nonbarbiturate agent for anesthesia induction | |
| KR101370096B1 (en) | Combination of alpha-2 receptor agonist (clonidin) and an anti-muscarinic agent (oxybutynin) for the treatment of sialorrhoea | |
| JPH0222229A (en) | Combination preparation used in treatment of disease or injury of nerve cell and nerve fiber | |
| US7834056B2 (en) | Pharmaceutical composition for gout | |
| US20220096475A1 (en) | Method for treating sarcoidosis-associated pulmonary hypertension | |
| AU2018357350B2 (en) | Delayed release deferiprone tablets and methods of using the same | |
| BG64540B1 (en) | Use of dexmedetomidine for sedative effect in patients in an intensive care unit | |
| EP3331509B1 (en) | Stable liquid injectable solution of midazolam and pentazocine | |
| Adachi et al. | Small dose midazolam or droperidol reduces the hypnotic dose of propofol at the induction of anaesthesia | |
| CN109172550B (en) | Composite anesthetic | |
| US11253488B2 (en) | Sublingual epinephrine tablets | |
| WO2022097764A1 (en) | Pharmaceutical composition comprising pregabalin and tianeptine for treating neuropathic pain | |
| CN110325214A (en) | Low-dose drugs for preventing and treating neure damage combine | |
| CN103263404A (en) | Composite anaesthetic | |
| MX2011001631A (en) | Treatment of anxiety disorders. | |
| US20190381034A1 (en) | Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases | |
| CN117797155B (en) | Pharmaceutical formulation against ketamine toxicity | |
| Singh et al. | Comparisons of tramadol with pethidine for prevention of post anaesthetic shivering in elective abdominal surgery | |
| CN112641765B (en) | Anti-fatigue pharmaceutical application of propofol | |
| Hossain et al. | Dexamethasone is cost-effective alternative to ondansetron in preventing Post-Operative Nausea and Vomiting | |
| JP2006008540A (en) | Cold remedy | |
| RU2664693C1 (en) | Method of patient preoperative preparation to ocular surgery | |
| CN1180789C (en) | Compound medicine for migraine | |
| RU2404976C1 (en) | Agent to reduce alcohol addiction, pharmaceutical composition, method for making thereof, medicinal agent and method of treating |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20231116 Address after: 434000 South of Fangyin Fourth Road and West of Jiuhao Road, Development Zone, Jingzhou City, Hubei Province Applicant after: Hubei Yike Pharmaceutical Co.,Ltd. Address before: Room 207, unit 4, building 1, No.3 guide North Road, Qufu City, Jining City, Shandong Province 273199 Applicant before: Han Wei |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |